Biology and therapy of immunoglobulin deposition diseases

Pathologic immunoglobulin deposition can lead to significant organ dysfunction, morbidity and mortality. This article examines the recent advances in the understanding of both host and protein factors in the pathogenesis of primary systemic amyloidosis and light chain deposition disease. Limitations of current therapy are reviewed and newer approaches including iododoxorubicin, dexamethasone, and high-dose therapy are discussed.